ROYALTY MONETIZATIONUp to $67.5 Million
Ruxience (marketed by Pfizer) is a biosimilar of Roche’s Rituxan (rituximab), an intravenously infused anti-CD20 monoclonal antibody that initially received FDA approval for non-Hodgkin’s lymphoma in November 1997 and went on to generate over $7 billion in annual peak sales. Today, Rituxan is approved across six indications and continues to generate over $6 billion in annual sales.
HCR purchased the right to receive all royalty payments made to Aptevo Therapeutics by Pfizer in respect of net sales of Ruxience. Aptevo monetized this non-strategic royalty interest to raise nondilutive capital to strengthen its financial position, providing additional capital cushion to fund its promising clinical programs and operations.
Note: This transaction also appears in the Royalty Monetization section under RUXIENCE.